Doly M, Cluzel J, Bonhomme B, Millerin M, Braquet P
Laboratoire de Biophysique, Faculté de Médecine, Clermont-Ferrand, France.
Acta Ophthalmol Scand. 1995 Apr;73(2):155-7. doi: 10.1111/j.1600-0420.1995.tb00658.x.
The alkaloid vincristine displays considerable toxicity, particularly for the retina. This type of retinopathy being an inflammatory disease, we measured the effects of a new hetrazepine platelet activating factor antagonist, BN 50730, on a vincristine-induced retinopathy in the rat. Retinal impairments were established by recording several parameters of the electroretinogram obtained from isolated retina. Our results indicate that 1) the increase in PIII duration induced by vincristine is significantly reduced by BN 50730 administration 2) the decrease in the amplitude of the PIII/b wave ratio caused by vincristine is partially inhibited by treatment with BN 50730. These experiments suggest that platelet activating factor is implicated in vincristine retinopathy and demonstrate the therapeutic effect of a specific antagonist of the mediator.
生物碱长春新碱具有相当大的毒性，尤其是对视网膜。这种类型的视网膜病变是一种炎症性疾病，我们测定了一种新型氮杂环庚烷血小板活化因子拮抗剂BN 50730对大鼠长春新碱诱导的视网膜病变的影响。通过记录从离体视网膜获得的视网膜电图的几个参数来确定视网膜损伤。我们的结果表明：1）给予BN 50730可显著降低长春新碱诱导的PIII持续时间的增加；2）BN 50730治疗可部分抑制长春新碱引起的PIII/b波比值幅度的降低。这些实验表明血小板活化因子与长春新碱视网膜病变有关，并证明了该介质特异性拮抗剂的治疗作用。
